Insider transactions

Norbert W Bischofberger

CIK 1190273 · PRESIDENT & CEO · last filed 2026-05-28

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure
$368.99M
Companies
4
Total Filings
95
Lifetime Open-Market Net
-$228.76M

Charts

Trading activity, where the exposure sits, and each trade against the stock price.

GILD price and trades

Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.

Shares held

Shares owned after each reported transaction on this company (direct holdings as reported).

Open-market buying and selling

by month

Dollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.

Exposure by company

latest
OfficerDirector10% owner* stale (no filing in 3 yrs)

Most recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.

Filer Profile

Reported Address
333 LAKESIDE DR
C/O GILEAD SCIENCES, INC.
FOSTER CITY, CA 94404
Related Filers
GILEAD SCIENCES, INC. — 102 joint filings, latest 2018-02-23
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
VIR Director 32,000 $10.37 $331.7K $0 4 2026-05-28
Kronos Bio, Inc. (KRON) Delisted PRESIDENT & CEO 2,811,004 $0.88 $2.47M $9.56M 11 2025-06-20
Morphic Holding, Inc. (MORF) Delisted Director — $56.99 — $0 6 2024-06-05
GILD EVP, R&D and CSO 2,346,795 $157.09 $368.66M -$238.32M 73 2018-02-23

Recent Filings · Page 2 of 10

95 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2023-11-17 Kronos Bio, Inc. (KRON) Delisted Buy (P) +1,731,056 $1.47M EDGAR
2023-06-02 Morphic Holding, Inc. (MORF) Delisted Grant (A) — $0 EDGAR
2023-02-17 Kronos Bio, Inc. (KRON) Delisted Grant (A) — $0 EDGAR
2022-06-10 Morphic Holding, Inc. (MORF) Delisted Grant (A) — $0 EDGAR
2022-05-19 Kronos Bio, Inc. (KRON) Delisted Buy (P) +597,129 $2.25M EDGAR
2022-04-29 Morphic Holding, Inc. (MORF) Delisted Grant (A) — $0 EDGAR
2022-02-17 Kronos Bio, Inc. (KRON) Delisted Grant (A) — $0 EDGAR
2021-12-08 Kronos Bio, Inc. (KRON) Delisted Buy (P) +14,356 $173.5K EDGAR
2021-06-17 Morphic Holding, Inc. (MORF) Delisted Grant (A) — $0 EDGAR
2020-12-11 Kronos Bio, Inc. (KRON) Delisted Grant (A) +198,124 $0 EDGAR
Showing 11–20 of 95
Page 2 of 10
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.